FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) Oxycodone XR Incorporating PODRAS(TM) Technology

TORONTO, May 26, 2015  -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA") has reviewed the Company's request for Fast Track designation for its abuse deterrent Rexista(TM) Oxycodone XR (Oxycodone HCl) extended-release tablets development program incorporating its Paradoxical OverDose Resistance Activating System ("PODRAS(TM)") and has concluded that it meets the criteria for Fast Track designation.

CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study

SYDNEY, AUSTRALIA--( May 26, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

• Final Data from the CAN-003 Phase II trial after 5 years of data collection
• Final Overall Survival data provided at least 16 months benefit for second remission ovarian cancer patients ("second remission patients") using CVac™
• Follows Progression Free Survival data showing 8 month benefit for second remission patients

Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") is pleased to announce that the final CVac data from the Phase II CAN-003 ovarian cancer clinical trial has shown a trend for a clinically meaningful improvement in Overall Survival ("OS") over standard of care ("SOC") in second remission patients.

Cellular Biomedicine Group Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program

SHANGHAI, China and PALO ALTO, Calif., May 22, 2015 -- Cellular Biomedicine Group Inc. (CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced encouraging clinical data from its Chimeric Antigen Receptor (CAR-T) CD30-positive Hodgkin's lymphoma immuno-oncology clinical development program. The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to be safe, feasible and efficient.

The data was presented by Dr. William (Wei) Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group, at the 10^th Annual World Stem Cells & Regenerative Medicine Congress in London, UK on May 21, 2015.

Ampio Pharmaceuticals Announces Positive Study Results on Optina™ for the Treatment of Diabetic Macular Edema

ENGLEWOOD, Colo., May 21, 2015  Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).

The OptimEyes trial, with FDA guidance, was designed to include a wide variety of DME patients, some of whom had no therapeutic options and were progressing to blindness. Intraocular injections may have been contraindicated in these patients (example-patients with glaucoma, prior vitrectomy etc...and were included in our trials).